On 19 May, advisors to the US Food and Drug Administration will meet virtually to discuss whether the antifibrotic benefits of a drug called Ocaliva from Intercept Pharmaceuticals outweigh the
toxicity risks for patients with this common fatty liver disease. A full regulatory decision is expected a month later. Approval of a second drug, resmetirom from Madrigal Pharmaceuticals, could soon follow.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: